Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 16/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 15/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 13/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29663909 | 0.97 | CHRNA4 (0.41) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL20483822 | 0.97 | CHRNA4 (0.41) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2011639 | 0.75 | — | — | |
| SCHEMBL21936152 | 0.74 | BPTF (0.40) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28989002 | 0.73 | GNAI3 (0.31) | — | |
| SCHEMBL24015163 | 0.70 | HSD11B1 (0.33) | — | |
| SCHEMBL28242316 | 0.70 | HSD11B1 (0.38) | — | |
| SCHEMBL15107220 | 0.69 | CHRNA4 (0.39) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20262863 | 0.68 | CHRNA7 (0.30) | CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15415289 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420973-B2 | Amide substituted indole compounds useful as TLR inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-23 | — | — | US | claimed |
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-25 | — | — | US | claimed |
| US-20200331920-A1 | AMIDE SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | PROTIX B.V. (NL) | 2020-10-22 | — | — | US | claimed |
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | claimed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | claimed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240182478-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION | 2024-06-06 | — | — | US | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182478-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | CHRNA4 3600/4885CHRNB2 3483/4885CHRNB4 3909/4885 |
| US-20080103125-A1 | Heterocylic antiviral compounds | CCR5, ACKR3, CXCR3 | CHRNA4 1539/4885CHRNB2 2332/4885CHRNB4 2390/4885 |
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | TLR7, TLR9, TLR1 | CHRNA4 928/4885CHRNB2 1385/4885CHRNB4 1440/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | CHRNA4 3600/4885CHRNB2 3483/4885CHRNB4 3909/4885 |
| US-11420973-B2 | Amide substituted indole compounds useful as TLR inhibitors | TLR9, TLR1, TLR7 | CHRNA4 2777/4885CHRNB2 2706/4885CHRNB4 2924/4885 |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | CHRNA4 1994/4885CHRNB2 1674/4885CHRNB4 1740/4885 |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA4, CHRNA2, CHRNE | CHRNA4 1/4885CHRNB2 5/4885CHRNB4 6/4885 |
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, TLR9 | CHRNA4 2564/4885CHRNB2 2811/4885CHRNB4 2813/4885 |
| US-20200331920-A1 | AMIDE SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR9, TLR1, TLR7 | CHRNA4 3066/4885CHRNB2 3015/4885CHRNB4 3379/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | CHRNA4 2783/4885CHRNB2 3559/4885CHRNB4 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.